Allogeneic bone marrow transplantation for Pearson's syndrome

Bone Marrow Transplant. 2007 May;39(9):563-5. doi: 10.1038/sj.bmt.1705638. Epub 2007 Mar 5.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / administration & dosage
  • Antilymphocyte Serum
  • Antineoplastic Agents / administration & dosage
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy
  • Aspergillosis, Allergic Bronchopulmonary / etiology
  • Base Sequence / genetics
  • Bone Marrow Transplantation*
  • DNA, Mitochondrial / genetics
  • Electron Transport / genetics
  • Female
  • Genetic Diseases, Inborn / genetics
  • Genetic Diseases, Inborn / pathology
  • Genetic Diseases, Inborn / therapy*
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / prevention & control
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Infant
  • Leukemia, Myeloid / therapy
  • Melphalan / administration & dosage
  • Mitochondrial Diseases / complications
  • Mitochondrial Diseases / genetics
  • Mitochondrial Diseases / pathology
  • Mitochondrial Diseases / therapy*
  • Myeloablative Agonists / administration & dosage
  • Sequence Deletion
  • Syndrome
  • Transplantation Conditioning*
  • Transplantation, Homologous
  • Treatment Failure
  • Vidarabine / analogs & derivatives

Substances

  • Antifungal Agents
  • Antilymphocyte Serum
  • Antineoplastic Agents
  • DNA, Mitochondrial
  • Immunosuppressive Agents
  • Myeloablative Agonists
  • Vidarabine
  • fludarabine
  • Melphalan